

SPECIALTY GUIDELINE MANAGEMENT

OBIZUR (antihemophilic factor [recombinant], porcine sequence)

POLICY

I. INDICATIONS

The indications below including FDA-approved indications and compendial uses are considered a covered benefit provided that all the approval criteria are met and the member has no exclusions to the prescribed therapy.

FDA-Approved Indication

Obizur is indicated for the treatment of bleeding episodes in adults with acquired hemophilia A.

Limitations of Use:

- A. Safety and efficacy of Obizur has not been established in patients with a baseline anti-porcine factor VIII inhibitor titer of greater than 20 BU.
- B. Obizur is not indicated for the treatment of congenital hemophilia A or von Willebrand disease

All other indications are considered experimental/investigational and are not a covered benefit.

II. CRITERIA FOR INITIAL APPROVAL

Acquired hemophilia A

Authorization of 1 month may be granted for treatment of acquired hemophilia A.

III. CONTINUATION OF THERAPY

All members (including new members) requesting authorization for continuation of therapy must meet ALL initial authorization criteria.

IV. REFERENCES

1. Obizur [package insert]. Westlake Village, CA: Baxter Healthcare Corporation; October 2014.
2. National Hemophilia Foundation. MASAC recommendations concerning products licensed for the treatment of hemophilia and other bleeding disorders. Revised October 2016. MASAC Document #246. Accessed December 1, 2016.
3. Gomperts E. Recombinant B domain deleted porcine factor VIII for the treatment of bleeding episodes in adults with acquired hemophilia A. *Expert Review of Hematology*. 2015 Aug;8(4):427-32.